Gilead to supply lenacapavir to Global Fund for up to 2M people

Gilead (GILD) announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir-Gilead’s twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of HIV as pre-exposure prophylaxis. Through the agreement, Gilead will supply enough doses to reach up to 2M people over three years in countries supported by the Global Fund, at no profit to Gilead. In October 2024, Gilead signed non-exclusive, royalty-free voluntary licensing agreements to manufacture and supply high-quality generic versions of lenacapavir in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle-income countries. Until licensed generic versions are available and can fully meet demand in LLMICs, Gilead also committed to providing Gilead-supplied lenacapavir for PrEP at no profit. Under this strategic partnership agreement with the Global Fund, countries supported by the Global Fund that are among the 120 high-incidence, resource-limited countries can access lenacapavir for PrEP. The Global Fund will prioritize early-access countries based on HIV epidemiology, national prevention strategies, and available resources. Gilead looks forward to partnering with other global aid organizations to further accelerate access to lenacapavir for PrEP in LLMICs.